Advertisement

Loss to Follow-Up Among Patients With Proliferative Diabetic Retinopathy in Clinical Practice

Published:March 21, 2020DOI:https://doi.org/10.1016/j.ajo.2020.03.011

      Purpose

      To determine the proportion of patients with proliferative diabetic retinopathy (PDR) who were counted as loss to follow-up (LTFU) patients and to investigate predictive factors.

      Design

      Retrospective cohort study.

      Methods

      Information was collected for 4,423 patients with PDR between April 30, 2012, and April 30, 2017. Two definitions of LTFU were used. Complete LTFU referred to the population who never returned to care within the study period. Interval LTFU referred to the population who did not adhere to clinical recommendations and missed scheduled appointments, resulting in intervals longer than 6 months or 1 year between 2 appointments. Age, average gross income, and insurance were assessed as potential predictors of interval LTFU.

      Results

      Among 4,423 patients with PDR, 2,407 (54.4%) and 2,320 (52.4%) were complete LTFU at 6 months and 1 year, respectively; 782 (17.7%) and 468 (10.6%) patients were interval LTFU for 6 months and 1 year, respectively. Age and average gross income were not found to be significant predictors of interval LTFU. Compared to self-pay, government and private insurance patients were more likely to be interval LTFU at 6 months (government, P = .035; private, P = .005). Private insurance patients were also more likely to be interval LTFU at 1 year (P = .003).

      Conclusions

      The identified complete LTFU rates were notably high and warrant further study. More than 1 of 6 patients were interval LTFU for at least 6 months, and 1 of 10 patients was interval LTFU for more than 1 year. Insurance status was significant in determining interval LTFU status. Consistent with other analyses, these results indicate that compliance with clinical appointments among patients with PDR is a substantial clinical challenge.
      To read this article in full you will need to make a payment

      References

        • Cho N.H.
        • Shaw J.E.
        • Karuranga S.
        • et al.
        IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045.
        Diabetes Res Clin Pract. 2018; 138: 271-281
        • Centers for Disease Control and Prevention
        National Center for Chronic Disease Prevention and Health Promotion. National Diabetes Statistics Report, 2017: Estimates of Diabetes and Its Burden in the United States.
        (Available at)
        • Gross J.G.
        • Glassman A.R.
        • Jampol L.M.
        • et al.
        Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial.
        JAMA. 2015; 314: 2137-2146
        • American Academy of Ophthalmology Retina/Vitreous Panel
        Preferred practice pattern® guidelines.
        in: Diabetic Retinopathy. American Academy of Ophthalmology, San Francisco, CA2017 (Available at:)
        • Aiello L.M.
        Perspectives on diabetic retinopathy.
        Am J Ophthalmol. 2003; 136: 122-135
        • Wubben T.J.
        • Johnson M.W.
        • Anti-VEGF Treatment Interruption Study Group
        Anti-vascular endothelial growth factor therapy for diabetic retinopathy: consequences of inadvertent treatment interruptions.
        Am J Ophthalmol. 2019; 204: 13-18
        • Obeid A.
        • Su D.
        • Patel S.N.
        • et al.
        Outcomes of eyes lost to follow-up with proliferative diabetic retinopathy that received panretinal photocoagulation versus intravitreal anti-vascular endothelial growth factor.
        Ophthalmology. 2019; 126: 407-413
        • Obeid A.
        • Gao X.
        • Ali F.S.
        • et al.
        Loss to follow-up in patients with proliferative diabetic retinopathy after panretinal photocoagulation or intravitreal anti-VEGF injections.
        Ophthalmology. 2018; 125: 1386-1392
        • US Internal Revenue Service
        SOI Tax Stats—Individual Income Tax Statistics—ZIP Code Data (SOI).
        (Available at:)
        • Hinkle J.W.
        • Flynn H.W.
        • Banta J.T.
        Patients presenting emergently with proliferative diabetic retinopathy: follow-up and factors associated with compliance.
        Retina. 2019; 40: 928-935
        • Lee D.J.
        • Lam B.L.
        • Arora S.
        • et al.
        Reported eye care utilization and health insurance status among US adults.
        Arch Ophthalmol. 2009; 127: 303-310
        • Elam A.R.
        • Andrews C.
        • Musch D.C.
        • Lee P.P.
        • Stein J.D.
        Large disparities in receipt of glaucoma care between enrollees in medicaid and those with commercial health insurance.
        Ophthalmology. 2017; 124: 1442-1448
        • Lee Y.H.
        • Chen A.X.
        • Varadaraj V.
        • et al.
        Comparison of access to eye care appointments between patients with Medicaid and those with private health care insurance.
        JAMA Ophthalmol. 2018; 136: 622-629
        • Hatef E.
        • Vanderver B.G.
        • Fagan P.
        • Albert M.
        • Alexander M.
        Annual diabetic eye examinations in a managed care Medicaid population.
        Am J Manag Care. 2015; 21: e297-e302
        • Sommers B.D.
        • Blendon R.J.
        • Orav E.J.
        • Epstein A.M.
        Changes in utilization and health among low-income adults after Medicaid expansion or expanded private insurance.
        JAMA Intern Med. 2016; 176: 1501-1509
        • Garfield R.
        • Orgera K.
        • Damico A.
        The Coverage Gap: Uninsured Poor Adults in States that Do Not Expand Medicaid.
        Henry J. Kaiser Family Foundation, 2019 (Available at)
        • Kaiser Family Foundation
        Health Insurance Coverage of the Total Population.
        (Available at)
        • Ganguli I.
        • Shi Z.
        • Orav E.J.
        • Rao A.
        • Ray K.N.
        • Mehrotra A.
        Declining use of primary care among commercially insured adults in the United States, 2008-2016.
        Ann Intern Med. 2020; 172: 240-247
        • Frith E.
        • Loprinzi P.D.
        Retinopathy and mortality.
        Diabetes Spectr. 2018; 31: 184-188
        • Zhu X.R.
        • Zhang Y.P.
        • Bai L.
        • Zhang X.L.
        • Zhou J.B.
        • Yang J.K.
        Prediction of risk of diabetic retinopathy for all-cause mortality, stroke and heart failure: evidence from epidemiological observational studies.
        Medicine (Baltimore). 2017; 96: e5894
        • Gross J.G.
        • Glassman A.R.
        • Liu D.
        • et al.
        Five-year outcomes of panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial.
        JAMA Ophthalmol. 2018; 136: 1138-1148